Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt 1439.00
MRNA's Cash to Debt is ranked lower than
63% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 57.55 vs. MRNA: 1439.00 )
MRNA' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 1439

F-Score: 3
Z-Score: -43.75
M-Score: -4.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
Operating margin (%) -186.93
MRNA's Operating margin (%) is ranked lower than
72% of the 795 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. MRNA: -186.93 )
MRNA' s 10-Year Operating margin (%) Range
Min: -2259.18   Max: -2.56
Current: -186.93

-2259.18
-2.56
Net-margin (%) -226.37
MRNA's Net-margin (%) is ranked lower than
72% of the 795 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. MRNA: -226.37 )
MRNA' s 10-Year Net-margin (%) Range
Min: -2269.84   Max: 2.56
Current: -226.37

-2269.84
2.56
ROA (%) -128.08
MRNA's ROA (%) is ranked lower than
64% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: -18.07 vs. MRNA: -128.08 )
MRNA' s 10-Year ROA (%) Range
Min: -450.79   Max: 1.06
Current: -128.08

-450.79
1.06
Revenue Growth (%) -73.00
MRNA's Revenue Growth (%) is ranked lower than
90% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. MRNA: -73.00 )
MRNA' s 10-Year Revenue Growth (%) Range
Min: -73   Max: 72
Current: -73

-73
72
EBITDA Growth (%) -60.70
MRNA's EBITDA Growth (%) is ranked lower than
96% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. MRNA: -60.70 )
MRNA' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 121.7
Current: -60.7

0
121.7
EPS Growth (%) -56.40
MRNA's EPS Growth (%) is ranked lower than
90% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. MRNA: -56.40 )
MRNA' s 10-Year EPS Growth (%) Range
Min: -61.3   Max: 101
Current: -56.4

-61.3
101
» MRNA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MRNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 10.68
MRNA's P/S is ranked lower than
51% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 19.71 vs. MRNA: 10.68 )
MRNA' s 10-Year P/S Range
Min: 0.5   Max: 134.19
Current: 10.68

0.5
134.19
EV-to-EBIT -18.51
MRNA's EV-to-EBIT is ranked higher than
67% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MRNA: -18.51 )
MRNA' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -18.51

Current Ratio 2.17
MRNA's Current Ratio is ranked lower than
83% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 4.09 vs. MRNA: 2.17 )
MRNA' s 10-Year Current Ratio Range
Min: 0.03   Max: 21.21
Current: 2.17

0.03
21.21
Quick Ratio 2.17
MRNA's Quick Ratio is ranked lower than
83% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 3.87 vs. MRNA: 2.17 )
MRNA' s 10-Year Quick Ratio Range
Min: 0.03   Max: 21.07
Current: 2.17

0.03
21.07

Valuation & Return

vs
industry
vs
history
Forward Rate of Return (Yacktman) -1436.39
MRNA's Forward Rate of Return (Yacktman) is ranked lower than
77% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -10.59 vs. MRNA: -1436.39 )
MRNA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -1436.39

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Marina Biotech, Inc., formerly known as Nastech Pharmaceutical Company Inc., was incorporated in Delaware in 1983. The Company is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies utilizing gene silencing approaches such as RNA interference ('RNAi') and blocking messenger RNA ('mRNA') translation. It has multiple proprietary technologies integrated into a nucleic acid-based drug discovery platform, with the capability to deliver novel nucleic acid-based therapeutics via systemic, local and oral administration to target a range of human diseases, based on the unique characteristics of the cells and organs involved in each disease. Its pipeline includes a clinical program in Familial Adenomatous Polyposis ('FAP') and preclinical programs in bladder cancer and myotonic dystrophy. In addition to its own, internally developed technologies, it has strategically in-licensed and further developed nucleic acid- and delivery-related technologies, forming an integrated drug discovery platform. It is employing its platform, through its own efforts and those of its partners, for the discovery of multiple nucleic acid-based therapeutics including siRNA, microRNA, and single stranded oligonucleotide-based drugs. It's competitors include Alnylam Pharmaceuticals, Benitec Biopharma, Dicerna Pharmaceuticals, miRagen Therapeutics, Mirna Therapeutics, Quark Pharmaceuticals, Regulus Therapeutics, Silence Therapeutics, and Tekmira Pharmaceuticals. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. It is also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials.
» More Articles for MRNA

Headlines

Articles On GuruFocus.com
x pie = y Jul 01 2011 
MDRNA Inc. Reports Operating Results (10-Q) Nov 15 2010 
MDRNA Inc. Reports Operating Results (10-Q) May 17 2010 
MDRNA Inc. Reports Operating Results (10-Q) Nov 12 2009 
MDRNA Inc. Reports Operating Results (10-Q) Jul 30 2009 
MDRNA Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
MARINA BIOTECH, INC. Financials Aug 26 2014
Marina Biotech Regains Compliance With Exchange Act Reporting Obligations Aug 20 2014
MARINA BIOTECH, INC. Files SEC form 10-Q, Quarterly Report Aug 19 2014
MARINA BIOTECH, INC. Files SEC form 10-Q, Quarterly Report Aug 07 2014
MARINA BIOTECH, INC. Files SEC form 10-K, Annual Report Aug 05 2014
MARINA BIOTECH, INC. Files SEC form 10-K, Annual Report Jul 22 2014
Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic... Jun 12 2014
Marina Biotech Receives Decision to Grant Japanese Patent for Its SMARTICLES Nucleic Acid Delivery... Jun 05 2014
Marina Biotech to Present at the LD Micro Invitational 2014 May 28 2014
MARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers May 19 2014
Marina Biotech Provides Organizational Update May 14 2014
MARINA BIOTECH, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial... May 13 2014
Marina Biotech Presents Clinical Data Demonstrating Delivery of Both Single and Double-Stranded... May 06 2014
Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based... Apr 02 2014
MARINA BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered... Mar 11 2014
Marina Biotech to Use Its RNAi, Antisense and microRNA Therapeutics Platform to Develop Drugs for... Mar 11 2014
MARINA BIOTECH, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities Feb 28 2014
Marina Biotech Continues to Build Worldwide Patent Protection for Its SMARTICLES(R) Nucleic Acid... Feb 27 2014
MARINA BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Feb 24 2014
Marina Biotech Announces $6 MM Convertible Preferred Stock Financing and Conversion to Common Stock... Feb 24 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK